Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | SARCLISA (isatuximab) - (ITHACA) | Smoldering multiple myeloma | Phase 3 | Ongoing | Intravenous | Oncology |
| Sanofi | Venglustat | Autosomal dominant polycystic kidney disease (ADPKD) | Phase 2/3 | Trial Discontinued | Oral | Genetic Disorder |
| Sanofi | Venglustat | Gaucher disease type 3 | Phase 2/3 | Ongoing | Oral | Genetic Disorder |
| Sanofi | Olipudase alfa | Acid sphingomyelinase deficiency (ASMD) | Phase 2/3 | Intravenous | Genetic Disorder | |
| Sanofi | Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD) | Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) | Phase 2b | Data Released | Oral | Gastroenterology |
| Sanofi | Ordesekimab (AMG 714/PRV-015) - (PROACTIVE) | Celiac disease | Phase 2b | Enrollment Conclusion | Subcutaneous | Gastroenterology |
| Sanofi | Amlitelimab (KY1005) - (TIDE-asthma) | Asthma | Phase 2 | Ongoing | Intravenous | Respiratory |
| Sanofi | Rilzabrutinib (PRN1008) - (WAIHA) | Warm autoimmune hemolytic anemia (wAIHA) | Phase 2 | Ongoing | Oral | Hematology |
